Fact Based List:
Top therapeutic areas (TAs) expected to drive biopharma market growth, 2022-2028
Submitted by Patty Jamison on Thu, 02/22/2024 - 16:56
- Oncology: +$142B
- CNS (Neurology/Central nervous system): +$56B
- Endocrine: +$38B
- Immuno-modulators: +$36B
- Metabolic diseases: +$40B
- Cardiovascular: +$17B
- Blood: +$10B
- Musculo-skeletal: +$11B
- Other TAs: +$98B
- Anti-infectives: -$44B
Notes: Expected market growth of top biopharma therapeutic areas from where they were in 2022 to 2028(estimate) in US billions.
Source: EY, How life sciences can make the right deals in a time of change, January 2024
Source URL: https://www.ey.com/en_gl/life-sciences/mergers-acquisitions-...
List Ratings: |
Lists You Might Also Be Interested In
- 2012: Top 10 Pharmaceutical Companies Contributing to Federal Candidates, Parties, and Outside Groups
- Top Ten Pharmaceutical Companies by 2017 Rx Sales
- Jeff Lagasse: 5 Hospital Pharmacy Trends For 2016
- Drug Channels: Top 4 Retail Pharmacy Chain Participation in 2018 Part D Preferred Pharmacy Networks
- Top 7 National Pharmacies by Specialty Drug Revenue
Login or register to post comments